KR100895031B1 - 지질 농후 플라크의 감소, 안정화 및 파열 방지 방법 - Google Patents

지질 농후 플라크의 감소, 안정화 및 파열 방지 방법 Download PDF

Info

Publication number
KR100895031B1
KR100895031B1 KR1020077012071A KR20077012071A KR100895031B1 KR 100895031 B1 KR100895031 B1 KR 100895031B1 KR 1020077012071 A KR1020077012071 A KR 1020077012071A KR 20077012071 A KR20077012071 A KR 20077012071A KR 100895031 B1 KR100895031 B1 KR 100895031B1
Authority
KR
South Korea
Prior art keywords
delete delete
pharmaceutically acceptable
pitavastatin
hydrate
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077012071A
Other languages
English (en)
Korean (ko)
Other versions
KR20070085508A (ko
Inventor
히데유키 코바야시
야스노부 요시나카
키미유키 시부야
Original Assignee
교와 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 교와 가부시키가이샤 filed Critical 교와 가부시키가이샤
Publication of KR20070085508A publication Critical patent/KR20070085508A/ko
Application granted granted Critical
Publication of KR100895031B1 publication Critical patent/KR100895031B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020077012071A 2004-12-10 2005-12-09 지질 농후 플라크의 감소, 안정화 및 파열 방지 방법 Expired - Fee Related KR100895031B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63453204P 2004-12-10 2004-12-10
US60/634,532 2004-12-10

Publications (2)

Publication Number Publication Date
KR20070085508A KR20070085508A (ko) 2007-08-27
KR100895031B1 true KR100895031B1 (ko) 2009-04-24

Family

ID=36587943

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077012071A Expired - Fee Related KR100895031B1 (ko) 2004-12-10 2005-12-09 지질 농후 플라크의 감소, 안정화 및 파열 방지 방법

Country Status (11)

Country Link
US (2) US20090275595A1 (enExample)
EP (1) EP1827440A4 (enExample)
JP (1) JP2008522955A (enExample)
KR (1) KR100895031B1 (enExample)
CN (1) CN101068548B (enExample)
AU (1) AU2005314810B2 (enExample)
CA (1) CA2590224C (enExample)
NZ (1) NZ554924A (enExample)
RU (1) RU2351337C1 (enExample)
TW (1) TW200619204A (enExample)
WO (1) WO2006064889A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100438872C (zh) * 2003-08-29 2008-12-03 兴和株式会社 2-[4-[2-(苯并咪唑-2-基-硫代)乙基]哌嗪-1-基]-n-[2,4-二(甲基硫代)-6-甲基-3-吡啶基]乙酰胺的制药用途
US8048083B2 (en) * 2004-11-05 2011-11-01 Dfine, Inc. Bone treatment systems and methods
WO2011081118A1 (ja) * 2009-12-29 2011-07-07 興和株式会社 経口投与用医薬組成物
JPWO2011081117A1 (ja) * 2009-12-29 2013-05-09 興和株式会社 経口投与用固形医薬組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01279866A (ja) * 1987-08-20 1989-11-10 Nissan Chem Ind Ltd キノリン系メバロノラクトン類
WO1998054153A1 (en) 1997-05-26 1998-12-03 Kowa Company, Ltd. Novel cyclic diamine compounds and medicine containing the same
JPH11515025A (ja) * 1995-11-02 1999-12-21 ワーナー−ランバート・コンパニー 脂質濃度を調節するための方法および医薬組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US6969711B2 (en) * 1997-05-26 2005-11-29 Kowa Company, Ltd. Cyclic diamine compounds and medicine containing the same
RU2235483C2 (ru) * 1998-11-25 2004-09-10 Нутри Фарма Аса Композиция, фармацевтический препарат и способ для профилактики и/или лечения и/или ослабления сердечно-сосудистых заболеваний
WO2001022962A1 (en) * 1999-09-30 2001-04-05 Merck & Co., Inc. Anti-hypercholesterolemic drug combination
IL153633A0 (en) * 2000-07-13 2003-07-06 Takeda Chemical Insustries Ltd Lipid-rich plaque inhibitors
HUP0301728A3 (en) * 2000-09-01 2004-05-28 Sankyo Co Hmg-coa reductase inhibiting pharmaceutical compositions and their use
US20060165605A1 (en) * 2001-12-28 2006-07-27 Ye-Mon Chen Process to regenerate fcc spent catalyst
MY140618A (en) * 2003-02-28 2009-12-31 Kowa Co Method for preparing acid addition salts of polyacidic basic compounds
US20060046996A1 (en) * 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01279866A (ja) * 1987-08-20 1989-11-10 Nissan Chem Ind Ltd キノリン系メバロノラクトン類
JPH11515025A (ja) * 1995-11-02 1999-12-21 ワーナー−ランバート・コンパニー 脂質濃度を調節するための方法および医薬組成物
WO1998054153A1 (en) 1997-05-26 1998-12-03 Kowa Company, Ltd. Novel cyclic diamine compounds and medicine containing the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Folia Pharmcol. Jpn. 118: 389-395 (2001)

Also Published As

Publication number Publication date
CN101068548B (zh) 2010-12-08
US20090275595A1 (en) 2009-11-05
RU2351337C1 (ru) 2009-04-10
EP1827440A4 (en) 2010-12-08
AU2005314810B2 (en) 2010-08-26
HK1111356A1 (en) 2008-08-08
TW200619204A (en) 2006-06-16
US20110207742A1 (en) 2011-08-25
CA2590224C (en) 2011-12-20
RU2007125976A (ru) 2009-01-20
NZ554924A (en) 2010-09-30
CN101068548A (zh) 2007-11-07
KR20070085508A (ko) 2007-08-27
AU2005314810A1 (en) 2006-06-22
EP1827440A1 (en) 2007-09-05
JP2008522955A (ja) 2008-07-03
WO2006064889A1 (en) 2006-06-22
CA2590224A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
KR101125462B1 (ko) 모다피닐의 제약 제제
EP0671171A1 (en) Use of HMG COA reductase inhibitor for the manufacture of a medicament for proventing or reducing risks of onset of cardiovascular events
EP1919466B9 (en) Formulations for treatment of lipoprotein abnormalities comprising a statin and a methylnicotinamide derivative
US20150272944A1 (en) Novel triglyceride reducing agent
US20110207742A1 (en) Method for reduction, stabilization and prevention of rupture of lipid rich plaque
CN100438872C (zh) 2-[4-[2-(苯并咪唑-2-基-硫代)乙基]哌嗪-1-基]-n-[2,4-二(甲基硫代)-6-甲基-3-吡啶基]乙酰胺的制药用途
KR20240040767A (ko) His 저감반응자의 치료
US6998422B2 (en) Lipid peroxide-lowering compositions
CN102065856A (zh) 决奈达隆与至少一种利尿药的组合及其治疗用途
JP2007513991A (ja) メタボリック症候群の処置のためのスタチンの使用
US20090062338A1 (en) Nitroxides for use in treating or preventing cardiovascular disease
HK1111356B (en) Method for reduction, stabilization and prevention of rupture of lipid rich plaque
TW202214237A (zh) 伐達司他之藥物－藥物交互作用的調節
AU2008201290B2 (en) Therapeutic treatment
EP0971714B1 (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia
WO2006011495A1 (ja) 高コレステロール血症及び／又は高トリグリセリド血症治療剤
CN1252714A (zh) 用于预防再狭窄的制剂
US20090088462A1 (en) Pharmaceutical Composition for Enhancing Adiponectin Production
HK1111632B (en) Novel triglyceride reducing agent
WO2005117853A1 (ja) 高脂血症治療剤及び糖尿病治療剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20120421

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20120421